News

From left, Ivonne Schulman, M.D., with Lina Shehadeh, Ph.D.

Miller School Researcher Receives $1.5 Million Grant to Study Role of Osteopontin in Heart Failure

A Miller School of Medicine researcher has received a $1.5 million grant from the National Heart, Lung and Blood Institute to study a potential new strategy for treating an intractable form of heart failure. “Prior studies have shown that lowering the level of a protein called osteopontin can ameliorate heart failure with reduced ejection fraction,” said Lina Shehadeh, Ph.D., assistant professor of medicine.

Read more on the Miller School website »

Stromal cells in the laboratory.

Mesenchymal Stromal Cells Shown to Prevent Lung and Skin Fibrosis, Restore Wound Healing

A cross-disciplinary group of researchers at the University of Miami Miller School of Medicine has found that allogeneic adipose-derived mesenchymal stromal cells (ASCs) will prevent lung and skin fibrosis, and restore wound healing.

Read more on the Miller School website »

51st Miami Winter Symposium Opens January 28

Stem Cells: Today’s Research Tomorrow’s Therapies will be the focus of the 51st Miami Winter Symposium, which will take place January 28-31 at the downtown Hyatt Regency Hotel January 28-31.

Read more on the Miller School website »

Six-minute walk test results improved with stem cell therapy.

Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty

Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further. Now Phase II randomized, placebo-controlled trial findings have verified their initial study.

Read more on the Miller School website »

Joshua M. Hare, M.D.

Study Shows Stem Cell Therapy Dosing Matters in Ischemic Cardiomyopathy

The Phase II TRIDENT study, led by Joshua M. Hare, M.D., and colleagues at the University of Miami Miller School of Medicine, found that a dose of 100 million allogeneic human mesenchymal stem cells, versus 20 million, was more effective in decreasing scar tissue and restoring left ventricular ejection fraction in study of 30 people with ischemic cardiomyopathy.

Read more on the Miller School website »

News Archives »